Please wait while the formulary information is being retrieved.
TESTOSTERONE ENANTHATE (TESTOSTERONE ENANTHATE)
- Androgen deficiency
- Male hypogonadism
- Bilateral anorchia
- Bilateral orchiectomy
- Chemotherapy-induced hypogonadism
- Cryptorchidism
- Delayed male puberty
- Gonadotropin releasing factor deficiency
- Hormone receptor positive breast cancer
- Klinefelter's syndrome
- Primary hypogonadism due to bilateral torsion of testes
- Primary hypogonadism due to orchitis
200 mg/mL intramuscular oil
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
200 mg/mL intramuscular oil
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
Androgen deficiency
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
Bilateral anorchia
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
Bilateral orchiectomy
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
Chemotherapy-induced hypogonadism
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
Cryptorchidism
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
Gonadotropin releasing factor deficiency
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
Hormone receptor positive breast cancer
- Inject 1 milliliter (200 mg) by intramuscular route every 2 weeks
- Inject 1 milliliter (200 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
Male hypogonadism
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
Primary hypogonadism due to bilateral torsion of testes
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
Primary hypogonadism due to orchitis
- Inject 0.25 milliliter (50 mg) by intramuscular route every 2 weeks
- Inject 0.25 milliliter (50 mg) by intramuscular route every 4 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 2 weeks
- Inject 2 milliliters (400 mg) by intramuscular route every 4 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
- Malignant tumor of male breast
- Pregnancy
- Prostatic carcinoma
Contraindicated
- Acute myocardial infarction
- Benign prostatic hyperplasia
- Cerebrovascular accident
- Chronic pulmonary disease
- Erythrocytosis
- Hypercholesterolemia
- Kidney disease with reduction in GFR
- Polycythemia vera
- Pulmonary thromboembolism
- Venous thrombosis
Severe
Moderate
- Chronic heart failure
- Diabetes mellitus
- Disease of liver
- Edema
- Gynecomastia
- Humoral hypercalcemia of malignancy
- Hypertension
- Obesity
- Sleep apnea
TESTOSTERONE ENANTHATE (TESTOSTERONE ENANTHATE)
- Androgen deficiency
- Male hypogonadism
- Bilateral anorchia
- Bilateral orchiectomy
- Chemotherapy-induced hypogonadism
- Cryptorchidism
- Delayed male puberty
- Gonadotropin releasing factor deficiency
- Hormone receptor positive breast cancer
- Klinefelter's syndrome
- Primary hypogonadism due to bilateral torsion of testes
- Primary hypogonadism due to orchitis
- Amenorrhea
- Bladder irritability
- Irregular menstrual periods
- Priapism
- Urinary tract infection
- Virilism
- Gynecomastia
- Mastalgia
More Frequent
Severe
Less Severe
- Benign prostatic hyperplasia
- Disease of liver
- Dizziness
- Edema
- Epididymitis
- Fatigue
- Flushing
- Hypercalcemia
- Hypertension
- Nausea
- Prostatic carcinoma
- Raised prostate specific antigen
- Sleep apnea
- Vomiting
- Abdominal pain with cramps
- Acne vulgaris
- Administration site infection
- Diarrhea
- Erectile dysfunction
- Headache disorder
- Increased pubic hair
- Injection site sequelae
- Insomnia
- Libido changes
- Testicular atrophy
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Acute respiratory distress syndrome
- Cerebrovascular accident
- Deep venous thrombosis
- Drug-induced hepatitis
- Erythrocytosis
- Heart failure
- Hepatic necrosis
- Leukopenia
- Malignant neoplasm of liver
- Peliosis hepatis
- Pulmonary thromboembolism
- Suicidal ideation
- Venous thrombosis
Less Severe
- Aggressive behavior
- Anorexia
- Depression
- Hostility
- Hypercholesterolemia
- Irritability
- Oligospermia
Contraindicated
None
Severe Precaution
Testosterone (Inj)
Safety and efficacy not established age<12 years. May cause premature epiphyseal closure.
- 1 Day – 12 Years
- Safety and efficacy not established age<12 years. May cause premature epiphyseal closure.
Management or Monitoring Precaution
None
Testosterone
- Severity Level:
1
- Additional Notes: Androgens contraindicated in pregnancy; risk of virilization of female fetus.
Contraindicated
Testosterone
Poss sev adv effects, premature epiphyseal closure, virilization of females
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Poss sev adv effects, premature epiphyseal closure, virilization of females |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Testosterone
General-Avoid use in the elderly unless indicated for confirmed hypogonadism. Urogenital-Increased risk of acute kidney injury. May exacerbate prostate cancer. Cardiovascular-Reports of venous thromboembolism, deep vein thrombosis and pulmonary embolism. Possible increased risk of atrial fibrillation.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | N | N | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- None
| Androgen deficiency | |
| E29.1 | Testicular hypofunction |
| Bilateral anorchia | |
| Q55.0 | Absence and aplasia of testis |
| Chemotherapy-induced hypogonadism | |
| E29.1 | Testicular hypofunction |
| Cryptorchidism | |
| Q53 | Undescended and ectopic testicle |
| Q53.0 | Ectopic testis |
| Q53.00 | Ectopic testis, unspecified |
| Q53.01 | Ectopic testis, unilateral |
| Q53.02 | Ectopic testes, bilateral |
| Q53.1 | Undescended testicle, unilateral |
| Q53.10 | Unspecified undescended testicle, unilateral |
| Q53.11 | Abdominal testis, unilateral |
| Q53.111 | Unilateral intraabdominal testis |
| Q53.112 | Unilateral inguinal testis |
| Q53.12 | Ectopic perineal testis, unilateral |
| Q53.13 | Unilateral high scrotal testis |
| Q53.2 | Undescended testicle, bilateral |
| Q53.20 | Undescended testicle, unspecified, bilateral |
| Q53.21 | Abdominal testis, bilateral |
| Q53.211 | Bilateral intraabdominal testes |
| Q53.212 | Bilateral inguinal testes |
| Q53.22 | Ectopic perineal testis, bilateral |
| Q53.23 | Bilateral high scrotal testes |
| Q53.9 | Undescended testicle, unspecified |
| R39.83 | Unilateral non-palpable testicle |
| R39.84 | Bilateral non-palpable testicles |
| Delayed male puberty | |
| E30.0 | Delayed puberty |
| Gonadotropin releasing factor deficiency | |
| E23.3 | Hypothalamic dysfunction, not elsewhere classified |
| Hormone receptor positive breast cancer | |
| C50 | Malignant neoplasm of breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.12 | Malignant neoplasm of central portion of breast, male |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.22 | Malignant neoplasm of upper-inner quadrant of breast, male |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.32 | Malignant neoplasm of lower-inner quadrant of breast, male |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.42 | Malignant neoplasm of upper-outer quadrant of breast, male |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.52 | Malignant neoplasm of lower-outer quadrant of breast, male |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.62 | Malignant neoplasm of axillary tail of breast, male |
| C50.621 | Malignant neoplasm of axillary tail of right male breast |
| C50.622 | Malignant neoplasm of axillary tail of left male breast |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.82 | Malignant neoplasm of overlapping sites of breast, male |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| C50.92 | Malignant neoplasm of breast of unspecified site, male |
| C50.921 | Malignant neoplasm of unspecified site of right male breast |
| C50.922 | Malignant neoplasm of unspecified site of left male breast |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast |
| Z17.0 | Estrogen receptor positive status [Er+] |
| Z19.1 | Hormone sensitive malignancy status |
| Klinefelter's syndrome | |
| Q98.0 | Klinefelter syndrome karyotype 47, XXY |
| Q98.1 | Klinefelter syndrome, male with more than two X chromosomes |
| Q98.4 | Klinefelter syndrome, unspecified |
| Male hypogonadism | |
| E29.1 | Testicular hypofunction |
| Primary hypogonadism due to bilateral torsion of testes | |
| E29.1 | Testicular hypofunction |
| Primary hypogonadism due to orchitis | |
| E29.1 | Testicular hypofunction |
| 0-9 | A-Z |
|---|---|
| C50 | Malignant neoplasm of breast |
| C50.1 | Malignant neoplasm of central portion of breast |
| C50.11 | Malignant neoplasm of central portion of breast, female |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.12 | Malignant neoplasm of central portion of breast, male |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| C50.122 | Malignant neoplasm of central portion of left male breast |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast |
| C50.2 | Malignant neoplasm of upper-inner quadrant of breast |
| C50.21 | Malignant neoplasm of upper-inner quadrant of breast, female |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast |
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast |
| C50.22 | Malignant neoplasm of upper-inner quadrant of breast, male |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast |
| C50.3 | Malignant neoplasm of lower-inner quadrant of breast |
| C50.31 | Malignant neoplasm of lower-inner quadrant of breast, female |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast |
| C50.32 | Malignant neoplasm of lower-inner quadrant of breast, male |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast |
| C50.4 | Malignant neoplasm of upper-outer quadrant of breast |
| C50.41 | Malignant neoplasm of upper-outer quadrant of breast, female |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast |
| C50.42 | Malignant neoplasm of upper-outer quadrant of breast, male |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast |
| C50.5 | Malignant neoplasm of lower-outer quadrant of breast |
| C50.51 | Malignant neoplasm of lower-outer quadrant of breast, female |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50.52 | Malignant neoplasm of lower-outer quadrant of breast, male |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast |
| C50.6 | Malignant neoplasm of axillary tail of breast |
| C50.61 | Malignant neoplasm of axillary tail of breast, female |
| C50.611 | Malignant neoplasm of axillary tail of right female breast |
| C50.612 | Malignant neoplasm of axillary tail of left female breast |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast |
| C50.62 | Malignant neoplasm of axillary tail of breast, male |
| C50.621 | Malignant neoplasm of axillary tail of right male breast |
| C50.622 | Malignant neoplasm of axillary tail of left male breast |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast |
| C50.8 | Malignant neoplasm of overlapping sites of breast |
| C50.81 | Malignant neoplasm of overlapping sites of breast, female |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast |
| C50.819 | Malignant neoplasm of overlapping sites of unspecified female breast |
| C50.82 | Malignant neoplasm of overlapping sites of breast, male |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast |
| C50.9 | Malignant neoplasm of breast of unspecified site |
| C50.91 | Malignant neoplasm of breast of unspecified site, female |
| C50.911 | Malignant neoplasm of unspecified site of right female breast |
| C50.912 | Malignant neoplasm of unspecified site of left female breast |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast |
| C50.92 | Malignant neoplasm of breast of unspecified site, male |
| C50.921 | Malignant neoplasm of unspecified site of right male breast |
| C50.922 | Malignant neoplasm of unspecified site of left male breast |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast |
| E23.3 | Hypothalamic dysfunction, not elsewhere classified |
| E29.1 | Testicular hypofunction |
| E29.1 | Testicular hypofunction |
| E29.1 | Testicular hypofunction |
| E29.1 | Testicular hypofunction |
| E29.1 | Testicular hypofunction |
| E30.0 | Delayed puberty |
| Q53 | Undescended and ectopic testicle |
| Q53.0 | Ectopic testis |
| Q53.00 | Ectopic testis, unspecified |
| Q53.01 | Ectopic testis, unilateral |
| Q53.02 | Ectopic testes, bilateral |
| Q53.1 | Undescended testicle, unilateral |
| Q53.10 | Unspecified undescended testicle, unilateral |
| Q53.11 | Abdominal testis, unilateral |
| Q53.111 | Unilateral intraabdominal testis |
| Q53.112 | Unilateral inguinal testis |
| Q53.12 | Ectopic perineal testis, unilateral |
| Q53.13 | Unilateral high scrotal testis |
| Q53.2 | Undescended testicle, bilateral |
| Q53.20 | Undescended testicle, unspecified, bilateral |
| Q53.21 | Abdominal testis, bilateral |
| Q53.211 | Bilateral intraabdominal testes |
| Q53.212 | Bilateral inguinal testes |
| Q53.22 | Ectopic perineal testis, bilateral |
| Q53.23 | Bilateral high scrotal testes |
| Q53.9 | Undescended testicle, unspecified |
| Q55.0 | Absence and aplasia of testis |
| Q98.0 | Klinefelter syndrome karyotype 47, XXY |
| Q98.1 | Klinefelter syndrome, male with more than two X chromosomes |
| Q98.4 | Klinefelter syndrome, unspecified |
| R39.83 | Unilateral non-palpable testicle |
| R39.84 | Bilateral non-palpable testicles |
| Z17.0 | Estrogen receptor positive status [Er+] |
| Z19.1 | Hormone sensitive malignancy status |
Formulary Reference Tool